BiotechTube

COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Oct 5, 2021 → Feb 28, 2023

NCT ID
NCT05047718

About COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)

COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose) is a approved stage product being developed by Sanofi for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT05047718. Target conditions include Covid19.

What happened to similar drugs?

3 of 15 similar drugs in Covid19 were approved

Approved (3) Terminated (5) Active (9)
✅Icosapent ethylAmarin CorporationApproved
✅bamlanivimabEli LillyApproved
✅Moderna mRNA-1273 COVID-19 vaccine + Pfizer BNT162b2 COVID-19 vaccineAllergy TherapeuticsApproved
❌AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
❌BaricitinibEli LillyPhase 3
🔄LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3
🔄Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05047718ApprovedCompleted

Competing Products

20 competing products in Covid19

See all competitors
ProductCompanyStageHype Score
AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
29
Favipiravir + NitazoxanideStrides PharmaPhase 2
35
Icosapent ethylAmarin CorporationApproved
25
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
25
Cytotoxic T LymphocytesTevogen BioPhase 1
19
DS-5670a + PlaceboDaiichi SankyoPhase 1/2
32
Pegylated Interferon-α2bZydus LifesciencesPhase 2
27
BaricitinibEli LillyPhase 3
32
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3
40
bamlanivimabEli LillyApproved
35
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222AstraZenecaPhase 1
25
Sacubitril / Valsartan Oral Tablet [Entresto] + PlaceboNovartisPhase 1/2
32
PirfenidoneRochePre-clinical
26
Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3
40
RemdesivirGilead SciencesPre-clinical
26
Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + CorticosteroidGilead SciencesPhase 3
40
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)PfizerPhase 3
36
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 VaccinePfizerPre-clinical
26
Tofacitinib 10 mg + PlaceboPfizerPhase 3
40
BNT162b2PfizerPhase 2
35